Cardiac glycosides correct aberrant splicing of IKBKAP -encoded mRNA in familial dysautonomia derived cells by suppressing expression of SRSF3

FEBS Journal

Volumn 280, Issue 15, 2013, Pages 3632-3646

  Liu, Bo ^a,b   Anderson, Sylvia L ^a   Qiu, Jinsong ^a   Rubin, Berish Y ^a  

^a FORDHAM UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

alternative splicing; cardiac glycoside; digoxin; familial dysautonomia; SRSF3

Indexed keywords

ACETYLDIGITOXIN; BUFALIN; CARDIAC GLYCOSIDE; DIGITONIN; DIGITOXIGENIN; DIGITOXIN; DIGOXIGENIN; DIGOXIN; MESSENGER RNA; OUABAGENIN; OUABAIN; SERINE ARGININE RICH PROTEIN SPLICING FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG EFFECT; DYSAUTONOMIA; EMBRYO; EXON; FIBROBLAST; GENE; GENE SEQUENCE; HUMAN; HUMAN CELL; IKBKAP GENE; INTRON; NERVE CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA SPLICING; WILD TYPE;

ALTERNATIVE SPLICING; CARDIAC GLYCOSIDE; DIGOXIN; FAMILIAL DYSAUTONOMIA; SRSF3;

ALTERNATIVE SPLICING; BASE SEQUENCE; BINDING SITES; CARDIAC GLYCOSIDES; CARRIER PROTEINS; CELL LINE; DIGOXIN; DRUG EVALUATION, PRECLINICAL; DYSAUTONOMIA, FAMILIAL; EXONS; GENE SILENCING; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN-SERINE-THREONINE KINASES; RNA SPLICING; RNA, MESSENGER; RNA-BINDING PROTEINS; SEQUENCE DELETION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84880334148     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12355     Document Type: Article

References (67)

1. Riley CM, Day RL, Greeley DM, &, Langford WS, (1949) Central autonomic dysfunction with defective lacrimation; report of five cases. Pediatrics 3, 468-478.
2. Axelrod FB, Nachtigal R, &, Dancis J, (1974) Familial dysautonomia: diagnosis, pathogenesis and management. Adv Pediatr 21, 75-96.
3. Axelrod FB, (1996) Familial Dysautonomia. In Primer on the Autonomic Nervous System (, Robertson D, Low PA, &, Polinsky RJ, eds), pp. 242-249. Academic Press, San Diego, CA.
4. Rubin BY, &, Anderson SL, (2008) The molecular basis of familial dysautonomia: overview, new discoveries and implications for directed therapies. Neuromolecular Med 10, 148-156.
5. Anderson SL, Coli R, Daly IW, Kichula EA, Rork MJ, Volpi SA, Ekstein J, &, Rubin BY, (2001) Familial dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet 68, 753-758.
6. Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, Liebert CB, Chadwick B, Idelson M, Reznik L, et al,. (2001) Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet 68, 598-605.
7. Cohen L, Henzel WJ, &, Baeuerle PA, (1998) IKAP is a scaffold protein of the IkappaB kinase complex. Nature 395, 292-296.
8. Otero G, Fellows J, Li Y, de Bizemont T, Dirac AM, Gustafsson CM, Erdjument-Bromage H, Tempst P, &, Svejstrup JQ, (1999) Elongator, a multisubunit component of a novel RNA polymerase II holoenzyme for transcriptional elongation. Mol Cell 3, 109-118.
9. Krappmann D, Hatada EN, Tegethoff S, Li J, Klippel A, Giese K, Baeuerle PA, &, Scheidereit C, (2000) The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component. J Biol Chem 275, 29779-29787.
10. Hawkes NA, Otero G, Winkler GS, Marshall N, Dahmus ME, Krappmann D, Scheidereit C, Thomas CL, Schiavo G, Erdjument-Bromage H, et al,. (2002) Purification and characterization of the human elongator complex. J Biol Chem 277, 3047-3052.
11. Holmberg C, Katz S, Lerdrup M, Herdegen T, Jäättelä M, Aronheim A, &, Kallunki T, (2002) A novel specific role for I kappa B kinase complex-associated protein in cytosolic stress signaling. J Biol Chem 277, 31918-31928.
12. Chen YT, Hims MM, Shetty RS, Mull J, Liu L, Leyne M, &, Slaugenhaupt SA, (2009) Loss of mouse IKBKAP, a subunit of elongator, leads to transcriptional deficits and embryonic lethality that can be rescued by human IKBKAP. Mol Cell Biol 29, 736-744.
13. Mehlgarten C, Jablonowski D, Wrackmeyer U, Tschitschmann S, Sondermann D, Jäger G, Gong Z, Byström AS, Schaffrath R, &, Breunig KD, (2010) Elongator function in tRNA wobble uridine modification is conserved between yeast and plants. Mol Microbiol 76, 1082-1094.
14. Rahl PB, Chen CZ, &, Collins RN, (2005) Elp1p, the yeast homolog of the FD disease syndrome protein, negatively regulates exocytosis independently of transcriptional elongation. Mol Cell 18, 841-853.
15. Johansen LD, Naumanen T, Knudsen A, Westerlund N, Gromova I, Junttila M, Nielsen C, Bøttzauw T, Tolkovsky A, Westermarck J, et al,. (2008) IKAP localizes to membrane ruffles with filamin A and regulates actin cytoskeleton organization and cell migration. J Cell Sci 121, 854-864.
16. Anderson SL, Qiu J, &, Rubin BY, (2003) Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia. Biochem Biophys Res Commun 306, 303-309.
17. Anderson SL, Qiu J, &, Rubin BY, (2003) EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia. Biochem Biophys Res Commun 310, 627-633.
18. Slaugenhaupt SA, Mull J, Leyne M, Cuajungco MP, Gill SP, Hims MM, Quintero F, Axelrod FB, &, Gusella JF, (2004) Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum Mol Genet 13, 429-436.
19. Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, Ganat YM, Menon J, Shimizu F, Viale A, et al,. (2009) Modeling pathogenesis and treatment of familial dysautonomia using patient specific iPSCs. Nature 461, 402-406.
20. Boone N, Loriod B, Bergon A, Sbai O, Formisano-Tréziny C, Gabert J, Khrestchatisky M, Nguyen C, Féron F, Axelrod FB, et al,. (2010) Olfactory stem cells, a new cellular model for studying molecular mechanisms underlying familial dysautonomia. PLoS One 5, e15590.
21. Keren H, Donyo M, Zeevi D, Maayan C, Pupko T, &, Ast G, (2010) Phosphatidylserine increases IKBKAP levels in familial dysautonomia cells. PLoS One 5, e15884.
22. Lee G, Ramirez CN, Kim H, Zeltner N, Liu B, Radu C, Bhinder B, Kim YJ, Choi IY, Mukherjee-Clavin B, et al,. (2012) Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol 30, 1244-1248.
23. Anderson SL, &, Rubin BY, (2005) Tocotrienols reverse IKAP and monoamine oxidase deficiencies in familial dysautonomia. Biochem Biophys Res Commun 336, 150-156.
24. Gold-von Simson G, &, Axelrod FB, (2006) Familial dysautonomia: update and recent advances. Curr Probl Pediatr Adolesc Health Care 36, 218-237.
25. Rubin BY, Anderson SL, &, Kapás L, (2008) Can the therapeutic efficacy of tocotrienols in neurodegenerative familial dysautonomia patients be measured clinically? Antioxid Redox Signal 10, 837-841.
26. Anderson SL, Liu B, Qiu J, Sturm AJ, Schwartz JA, Peters AJ, Sullivan KA, &, Rubin BY, (2012) Nutraceutical-mediated restoration of wild-type levels of IKBKAP-encoded IKAP protein in familial dysautonomia-derived cells. Mol Nutr Food Res 56, 570-579.
27. McPhie DC, (2004) Old drugs, new uses: solving a Hatch-Waxman patent predicament. Food Drug Law J 59, 155-168.
28. Aronson JK, (2007) Old drugs-new uses. Br J Clin Pharmacol 64, 563-565.
29. Chong CR, &, Sullivan DJ Jr, (2007) New uses for old drugs. Nature 448, 645-646.
30. Smith TW, Butler VP Jr, &, Haber E, (1969) Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. N Engl J Med 281, 1212-1216.
31. Ibrahim EC, Hims MM, Shomron N, Burge CB, Slaugenhaupt SA, &, Reed R, (2007) Weak definition of IKBKAP exon 20 leads to aberrant splicing in familial dysautonomia. Hum Mutat 28, 41-53.
32. Hims MM, Ibrahim EC, Leyne M, Mull J, Liu L, Lazaro C, Shetty RS, Gill S, Gusella JF, Reed R, et al,. (2007) Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomia. J Mol Med 85, 149-161.
33. Stamm S, Riethoven JJ, Le Texier V, Gopalakrishnan C, Kumanduri V, Tang Y, Barbosa-Morais NL, &, Thanaraj TA, (2006) ASD: a bioinformatics resource on alternative splicing. Nucleic Acids Res 34, D46-55.
34. Hims MM, Shetty RS, Pickel J, Mull J, Leyne M, Liu L, Gusella JF, &, Slaugenhaupt SA, (2007) A humanized IKBKAP transgenic mouse models a tissue-specific human splicing defect. Genomics 90, 389-396.
35. Dietrich P, Alli S, Shanmugasundaram R, &, Dragatsis I, (2012) IKAP expression levels modulate disease severity in a mouse model of familial dysautonomia. Hum Mol Genet 21, 5078-5090.
36. Stoilov P, Lin CH, Damoiseaux R, Nikolic J, &, Black DL, (2008) A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators. Proc Natl Acad Sci USA 105, 11218-11223.
37. Änkö M-L, Müller-McNicoll M, Brandl H, Curk T, Gorup C, Henry I, Ule J, &, Neugebauer KM, (2012) The RNA-binding landscapes of two SR proteins reveal unique functions and binding to diverse RNA classes. Genome Biol 13, R17.
38. House AE, &, Lynch KW, (2008) Regulation of alternative splicing: more than just the ABCs. J Biol Chem 283, 1217-1221.
39. Erkelenz S, Mueller WF, Evans MS, Busch A, Schöneweis K, Hertel KJ, &, Schaal H, (2013) Position-dependent splicing activation and repression by SR and hnRNP proteins rely on common mechanisms. RNA 19, 96-102.
40. Sen S, Talukdar I, &, Webster NJ, (2009) SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing. Mol Cell Biol 29, 871-880.
41. Mabon SA, &, Misteli T, (2005) Differential recruitment of pre-mRNA splicing factors to alternatively spliced transcripts in vivo. PLoS Biol 3, e374.
42. Galiana-Arnoux D, Lejeune F, Gesnel MC, Stevenin J, Breathnach R, &, Del Gatto-Konczak F, (2003) The CD44 alternative v9 exon contains a splicing enhancer responsive to the SR proteins 9G8, ASF/SF2, and SRp20. J Biol Chem 278, 32943-32953.
43. Ling IF, &, Estus S, (2010) Role of SFRS13A in low-density lipoprotein receptor splicing. Hum Mutat 31, 702-709.
44. Gonçalves V, Matos P, &, Jordan P, (2009) Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum Mol Gene 18, 3696-3707.
45. Gromak N, Talotti G, Proudfoot NJ, &, Pagani F, (2008) Modulating alternative splicing by cotranscriptional cleavage of nascent intronic RNA. RNA 14, 359-366.
46. Sterne-Weiler T, Howard J, Mort M, Cooper DN, &, Sanford JR, (2011) Loss of exon identity is a common mechanism of human inherited disease. Genome Res 21, 1563-1571.
47. Lukas J, Gao DQ, Keshmeshian M, Wen WH, Tsao-Wei D, Rosenberg S, &, Press MF, (2001) Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 61, 3212-3219.
48. Feltes CM, Kudo A, Blaschuk O, &, Byers SW, (2002) An alternatively spliced cadherin-11 enhances human breast cancer cell invasion. Cancer Res 62, 6688-6697.
49. Ghigna C, Valacca C, &, Biamonti G, (2008) Alternative splicing and tumor progression. Curr Genomics 9, 556-570.
50. Brinkman BM, (2004) Splice variants as cancer biomarkers. Clin Biochem 37, 584-594.
51. Grosso AR, Martins S, &, Carmo-Fonseca M, (2008) The emerging role of splicing factors in cancer. EMBO Rep 9, 1087-1093.
52. Stickeler E, Kittrell F, Medina D, &, Berget SM, (1999) Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 18, 3574-3582.
53. Jia R, Li C, McCoy JP, Deng CX, &, Zheng ZM, (2010) SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance. Int J Biol Sci 6, 806-826.
54. He X, Arslan AD, Pool MD, Ho TT, Darcy KM, Coon JS, &, Beck WT, (2011) Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene 30, 356-365.
55. Stenkvist B, Bengtsson E, Eriksson O, Holmquist J, Nordin B, &, Westman-Naeser S, (1979) Cardiac glycosides and breast cancer. Lancet 1, 563.
56. Newman RA, Yang P, Pawlus AD, &, Block KI, (2008) Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8, 36-49.
57. Lõpez-Lázaro M, (2007) Digitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved. Expert Opin Ther Targets 11, 1043-1053.
58. Beheshti Zavareh R, Lau KS, Hurren R, Datti A, Ashline DJ, Gronda M, Cheung P, Simpson CD, Liu W, Wasylishen AR, et al,. (2008) Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. Cancer Res 68, 6688-6697.
59. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, et al,. (2008) Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA 105, 19579-19586.
60. Hashimoto S, Jing Y, Kawazoe N, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, &, Nakaya K, (1997) Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk Res 21, 875-883.
61. Mijatovic T, De Nève N, Gailly P, Mathieu V, Haibe-Kains B, Bontempi G, Lapeira J, Decaestecker C, Facchini V, &, Kiss R, (2008) Nucleolus and c-Myc: potential targets of cardenolide-mediated antitumor activity. Mol Cancer Ther 7, 1285-1296.
62. Xie Z, (2003) Molecular mechanisms of Na/K-ATPase-mediated signal transduction. Ann N Y Acad Sci 986, 497-503.
63. Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, &, Schmid RA, (2006) Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 66, 5867-5874.
64. Manna SK, Sreenivasan Y, &, Sarkar A, (2006) Cardiac glycoside inhibits IL-8-induced biological responses by downregulating IL-8 receptors through altering membrane fluidity. J Cell Physiol 207, 195-207.
65. Wang Z, Zheng M, Li Z, Li R, Jia L, Xiong X, Southall N, Wang S, Xia M, Austin CP, et al,. (2009) Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. Cancer Res 69, 6556-6564.
66. Prassas I, Karagiannis GS, Batruch I, Dimitromanolakis A, Datti A, &, Diamandis EP, (2011) Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. Mol Cancer Ther 10, 2083-2093.
67. Rubin BY, Anderson SL, Sullivan SA, Williamson BD, Carswell EA, &, Old LJ, (1985) Purification and characterization of a human tumor necrosis factor from the LuKII cell line. Proc Natl Acad Sci USA 82, 6637-6641.